These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30349889)

  • 1. Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
    Salta S; Papageorgiou L; Larsen AK; Van Dreden P; Soulier C; Cokkinos DV; Elalamy I; Gerotziafas GT
    Res Pract Thromb Haemost; 2018 Oct; 2(4):696-707. PubMed ID: 30349889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.
    Bar J; David A; Khader T; Mulcare M; Tedeschi C
    Prehosp Disaster Med; 2017 Oct; 32(5):580-587. PubMed ID: 28625215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism.
    Dirienzo L; Vitulli A; Mancazzo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Blood Transfus; 2022 Nov; 20(6):505-515. PubMed ID: 34967721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
    Wong PC; Crain EJ; Watson CA; Xin B
    J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
    Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
    PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
    Gantioqui J; Stevic I; Atkinson H; Chan AKC
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an acidic environment on coagulation dynamics.
    Gissel M; Brummel-Ziedins KE; Butenas S; Pusateri AE; Mann KG; Orfeo T
    J Thromb Haemost; 2016 Oct; 14(10):2001-2010. PubMed ID: 27431334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants in point-of-care monitoring: an ex-vivo study.
    Klages M; Raimann FJ; Philipp AL; Lindhoff-Last E; Zacharowski K; Mutlak H
    Minerva Anestesiol; 2021 May; 87(5):514-522. PubMed ID: 33591135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass.
    Nadtochiy SM; Stefanos T; Angona RE; Lebedko N; Baldzizhar A; Feng C; Eaton MP
    Anesth Analg; 2022 Jul; 135(1):52-59. PubMed ID: 35389372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation.
    Jaffer IH; Fredenburgh JC; Stafford A; Whitlock RP; Weitz JI
    Ann Thorac Surg; 2020 Aug; 110(2):582-590. PubMed ID: 31877292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation by factor Xa inhibitors.
    Orfeo T; Butenas S; Brummel-Ziedins KE; Gissel M; Mann KG
    J Thromb Haemost; 2010 Aug; 8(8):1745-53. PubMed ID: 20492473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.